Caffeic acid phenethyl ester

Name: Caffeic acid phenethyl ester
Brand: MedChemExpress
SKU: HY-N0274
Rating: 5.0 (14 reviews)

Cat. No.: HY-N0274 Purity: 99.96%: FAQs
Data Sheet SDS COA Handling Instructions Technical Support

Caffeic acid phenethyl ester is a NF-κB inhibitor.

For research use only. We do not sell to patients.

Caffeic acid phenethyl ester Chemical Structure

CAS No. : 104594-70-9

Size	Stock	Quantity

Free Sample (0.1 - 0.5 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	Get quote
10 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 14 publication(s) in Google Scholar

Other Forms of Caffeic acid phenethyl ester:

Caffeic acid In-stock

12 Publications Citing Use of MCE Caffeic acid phenethyl ester

: Caffeic acid phenethyl ester purchased from MedChemExpress. Usage Cited in: Mediat Inflamm. 2020 Jun 6;2020:4321912. [Abstract]; Immunofluorescence results show that the nucleus of agonist-CD137 group clearly changed from red to yellow, indicating NF-κB translocation has occurred in these cells. However, pretreatment with inhibitor of Caffeic acid phenethyl ester (CAPE) blocks the effect of CD137 signaling on the nuclear translocation of NF-κB .

: Caffeic acid phenethyl ester purchased from MedChemExpress. Usage Cited in: Mediat Inflamm. 2020 Jun 6;2020:4321912. [Abstract]; Western blot analysis reveals that CD137 signaling broadly increased the expression of NF-κB in the nucleus of HUVECs but decreased upon CAPE treatment.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Caffeic acid phenethyl ester is a NF-κB inhibitor.

IC₅₀ & Target^[1]

NF-κB

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	26.8 μM Compound: 2; CAPE	Cytotoxicity against VHL-deficient human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-deficient human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
786-0	IC₅₀	43.8 μM Compound: 2; CAPE	Cytotoxicity against VHL-positive human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-positive human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
A2780	EC₅₀	3.5 μM Compound: 17; CAPE	Cytotoxicity against human A2780 cells measured after 96 hrs by SRB assay Cytotoxicity against human A2780 cells measured after 96 hrs by SRB assay	[PMID: 31158743]
A549	IC₅₀	26.8 μM Compound: 1, CAPE	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 20673727]
A549	EC₅₀	27.9 μM Compound: 14	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 12027739]
A549	IC₅₀	80 μM Compound: 2; CAPE	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33210536]
A549	IC₅₀	83.6 μM Compound: III-19	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 18952420]
A549	IC₅₀	9.72 μM Compound: CAPE	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 26638042]
B16-BL6	EC₅₀	6.79 μM Compound: 14	Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 12027739]
B16-F10	IC₅₀	10.68 μM Compound: CAPE	Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 26638042]
Bel-7402	IC₅₀	5.5 μM Compound: III-19	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 18952420]
BEL-7404 tumor cell line	IC₅₀	14.5 μM Compound: 1, CAPE	Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay	[PMID: 20673727]
BeWo	IC₅₀	2.96 μM Compound: I-18	Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
BGC-823	IC₅₀	19.3 μM Compound: 1, CAPE	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 20673727]
BV-2	IC₅₀	6.4 μM Compound: 1, CAPE	Inhibition of nitric oxide production in LPS-stimulated mouse BV2 cells treated 3 hrs before LPS addition measured after 24 hrs by Griess assay Inhibition of nitric oxide production in LPS-stimulated mouse BV2 cells treated 3 hrs before LPS addition measured after 24 hrs by Griess assay	[PMID: 23870700]
BV-2	IC₅₀	6.4 μM Compound: 1, CAPE	Antineuroinflammatory activity in mouse BV2 cells assessed as reduction of LPS-induced nitric oxide production treated 3 hrs before LPS addition measured after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as reduction of LPS-induced nitric oxide production treated 3 hrs before LPS addition measured after 24 hrs by Griess assay	[PMID: 23726032]
BV-2	IC₅₀	6.4 μM Compound: 1, CAPE	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 3 hrs followed by LPS challenge measured after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 3 hrs followed by LPS challenge measured after 24 hrs by Griess assay	[PMID: 24697335]
Caco-2	IC₅₀	11.35 μM Compound: CAPE	Antiproliferative activity against human Caco2 cells after 72 hrs by MTT assay Antiproliferative activity against human Caco2 cells after 72 hrs by MTT assay	[PMID: 26638042]
CNE	IC₅₀	54 μM Compound: 1, CAPE	Cytotoxicity against human CNE cells after 72 hrs by MTT assay Cytotoxicity against human CNE cells after 72 hrs by MTT assay	[PMID: 20673727]
DU-145	IC₅₀	16 μM Compound: CAPE	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 27979593]
ECa-109 cell line	IC₅₀	42.6 μM Compound: 1, CAPE	Cytotoxicity against human ECA109 cells after 72 hrs by MTT assay Cytotoxicity against human ECA109 cells after 72 hrs by MTT assay	[PMID: 20673727]
ECa-109 cell line	IC₅₀	47.5 μM Compound: CAPE	Antiproliferative activity against human ECA109 cells after 48 hrs by MTT assay Antiproliferative activity against human ECA109 cells after 48 hrs by MTT assay	[PMID: 27979593]
FaDu	EC₅₀	12.1 μM Compound: 17; CAPE	Cytotoxicity against human FADU cells measured after 96 hrs by SRB assay Cytotoxicity against human FADU cells measured after 96 hrs by SRB assay	[PMID: 31158743]
HeLa	IC₅₀	0.068 μg/mL Compound: 9	Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA	[PMID: 19942440]
HeLa	EC₅₀	2.36 μM Compound: 14	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 12027739]
HeLa	IC₅₀	33 μM Compound: CAPE	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27979593]
HeLa	IC₅₀	37.98 μM Compound: I-18	Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
HeLa	IC₅₀	8.8 μM Compound: 1, CAPE	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 20673727]
HepG2	IC₅₀	40.87 μM Compound: I-18	Antitumor activity against human HepG2 cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human HepG2 cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
HL-60	IC₅₀	16.65 μM Compound: I-18	Antitumor activity against human HL60 cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human HL60 cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
HL-60	IC₅₀	9.8 μM Compound: 1, CAPE	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20673727]
HT-1080	EC₅₀	9.5 μM Compound: 14	Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 12027739]
HT-29	EC₅₀	> 30 μM Compound: 17; CAPE	Cytotoxicity against human HT-29 cells measured after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells measured after 96 hrs by SRB assay	[PMID: 31158743]
HUVEC	EC₅₀	8 μM Compound: CAPE	Cytoprotective activity against H2O2-induced oxidative stress in HUVEC cells after 18 hrs by Cell-Titer Blue assay Cytoprotective activity against H2O2-induced oxidative stress in HUVEC cells after 18 hrs by Cell-Titer Blue assay	[PMID: 20598894]
IMR-32	IC₅₀	5 μM Compound: 2; CAPE	Cytotoxicity against human IMR-32 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human IMR-32 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33210536]
J774.1	IC₅₀	4.8 μM Compound: CAPE	Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs by Griess reagent assay Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs by Griess reagent assay	[PMID: 15974608]
JJN-3	IC₅₀	30 μM Compound: 2; CAPE	Growth inhibition of human JJN-3 cells after 48 hrs by PrestoBlue cell viability assay Growth inhibition of human JJN-3 cells after 48 hrs by PrestoBlue cell viability assay	[PMID: 33210536]
K562	IC₅₀	46 μM Compound: 1, CAPE	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 20673727]
KB	IC₅₀	45.2 μM Compound: 1, CAPE	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 20673727]
KMM-1	IC₅₀	37.5 μM Compound: 2; CAPE	Growth inhibition of human KMM-1 cells after 48 hrs by PrestoBlue cell viability assay Growth inhibition of human KMM-1 cells after 48 hrs by PrestoBlue cell viability assay	[PMID: 33210536]
LNCaP	IC₅₀	33.7 μM Compound: 2, CAPE	Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 24 hrs by WST-1 assay Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 24 hrs by WST-1 assay	[PMID: 24080105]
LNCaP	IC₅₀	6.2 μM Compound: 2, CAPE	Antiandrogenic activity in human LNCAP cells assessed as reduction in DHT-stimulated PSA release after 24 hrs by ELISA Antiandrogenic activity in human LNCAP cells assessed as reduction in DHT-stimulated PSA release after 24 hrs by ELISA	[PMID: 24080105]
LS174T	IC₅₀	9.9 μM Compound: 1, CAPE	Cytotoxicity against human LS 174T cells after 72 hrs by MTT assay Cytotoxicity against human LS 174T cells after 72 hrs by MTT assay	[PMID: 20673727]
Macrophage	IC₅₀	15 μM Compound: CAPE	Inhibition of LPS-induced NO production in ddY mouse macrophages after 20 hrs by Griess reagent assay Inhibition of LPS-induced NO production in ddY mouse macrophages after 20 hrs by Griess reagent assay	[PMID: 15270564]
MCF7	EC₅₀	12.1 μM Compound: 17; CAPE	Cytotoxicity against human MCF7 cells measured after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells measured after 96 hrs by SRB assay	[PMID: 31158743]
MCF7	IC₅₀	26.7 μM Compound: III-19	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 18952420]
MCF7	IC₅₀	28.8 μM Compound: CAPE	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 27979593]
NIH3T3	EC₅₀	21.4 μM Compound: 17; CAPE	Cytotoxicity against mouse NIH/3T3 cells measured after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells measured after 96 hrs by SRB assay	[PMID: 31158743]
PC-12	IC₅₀	2 μM Compound: CAPE	Neuroprotection activity in rat PC12 cells assessed as reduction in H2O2-induced cell death preincubated for 3 hrs followed by H2O2 addition and measured after 3 hrs by MTS assay Neuroprotection activity in rat PC12 cells assessed as reduction in H2O2-induced cell death preincubated for 3 hrs followed by H2O2 addition and measured after 3 hrs by MTS assay	[PMID: 30928712]
PC-3	IC₅₀	10.15 μM Compound: CAPE	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 26638042]
PC-3	IC₅₀	51.4 μM Compound: 2, CAPE	Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue assay Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue assay	[PMID: 24080105]
PC-3	IC₅₀	91 μM Compound: 1, CAPE	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20673727]
Peritoneal macrophage	IC₅₀	4.31 μM Compound: 5; CAPE	Anti-inflammatory activity in ICR mouse peritoneal macrophages assessed inhibition of LPS-induced TNF-alpha production preincubated for 30 to 60 mins followed by LPS stimulation measured after 24 hrs by ELISA Anti-inflammatory activity in ICR mouse peritoneal macrophages assessed inhibition of LPS-induced TNF-alpha production preincubated for 30 to 60 mins followed by LPS stimulation measured after 24 hrs by ELISA	[PMID: 29202400]
Peritoneal macrophage cell	IC₅₀	11 μM Compound: CAPE	Hepatoprotective activity in ddY mouse peritoneal macrophages assessed as inhibition of LPS-induced nitric oxide production after 20 hrs by Griess method relative to untreated control Hepatoprotective activity in ddY mouse peritoneal macrophages assessed as inhibition of LPS-induced nitric oxide production after 20 hrs by Griess method relative to untreated control	[PMID: 19775895]
RAW264.7	EC₅₀	0.193 μM Compound: Table 1, R23C1	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells assessed as nitrite accumulation administered 1 hr before LPS challenge and measured after 24 hrs by Griess reagent assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells assessed as nitrite accumulation administered 1 hr before LPS challenge and measured after 24 hrs by Griess reagent assay	[PMID: 18667320]
RAW264.7	IC₅₀	3.8 μM Compound: CAPE	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 10 mins prior to LPS-challenge measured after 18 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 10 mins prior to LPS-challenge measured after 18 hrs by Griess method	[PMID: 22831798]
RAW264.7	EC₅₀	4.518 μM Compound: Table 1, R23C1	Cytotoxicity against mouse RAW264.7 cells assessed as cell survival after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as cell survival after 24 hrs by MTT assay	[PMID: 18667320]
RAW264.7	IC₅₀	9.3 μM Compound: CAPE	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method	[PMID: 28561586]
RCC4	IC₅₀	14 μM Compound: 2; CAPE	Cytotoxicity against VHL-deficient human RCC4 cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-deficient human RCC4 cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
RCC4/VHL	IC₅₀	29.1 μM Compound: 2; CAPE	Cytotoxicity against VHL-positive human RCC4/VHL cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-positive human RCC4/VHL cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
SGC-7901	IC₅₀	14.26 μM Compound: I-18	Antitumor activity against human SGC7901 cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human SGC7901 cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
SiHa	IC₅₀	66.92 μM Compound: I-18	Antitumor activity against human SiHa cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human SiHa cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
SW-1736	EC₅₀	4.7 μM Compound: 17; CAPE	Cytotoxicity against human SW1736 cells measured after 96 hrs by SRB assay Cytotoxicity against human SW1736 cells measured after 96 hrs by SRB assay	[PMID: 31158743]

In Vitro

Caffeic acid phenethyl ester is a NF-κB inhibitor. Cell survival and proliferation of CRPC cell lines are all significantly suppressed by Caffeic acid phenethyl ester (CAPE) treatment dose-dependently. The growth inhibitory effect of Caffeic acid phenethyl ester is evident within 24 hours of treatment but the suppressive effect accumulates over time. The IC₅₀ of 24, 48, 72, and 96 h Caffeic acid phenethyl ester treatment on LNCaP 104-R1 cells is 64.0, 30.5, 20.5, and 18.0 μM, respectively. Colony formation assay reveals that treatment with 10 μM Caffeic acid phenethyl ester reduces colony formation of LNCaP 104-R1 cells by 90% while treatment with 20 μM Caffeic acid phenethyl ester completely blocks the formation of LNCaP 104-R1 colonies. Flow cytometric analysis reveals a reduction of cells in the S phase and G2/M phase but an increase of cells in the G1 phase population in LNCaP 104-R1 cells under Caffeic acid phenethyl ester treatment. Caffeic acid phenethyl ester treatment also significantly decreases protein levels of fatty acid synthase (FAS), retinoblastoma protein (Rb), phospho-Rb Ser807/811, c-Myc, p70S6kinase, phospho-p70S6kinase Thr421/Ser424, Skp2, p90RSK, and NF-κB p65^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Administration of Caffeic acid phenethyl ester (CAPE) by gavage (10 mg/kg body weight per day) for eight weeks results in 50% reduction of tumor volume, suggesting that Caffeic acid phenethyl ester treatment retards the growth of LNCaP 104-R1 xenografts. Caffeic acid phenethyl ester gavage slows down the tumor growth of LNCaP 104-R1 cells, which is consistent with our observation that Caffeic acid phenethyl ester treatment induces cell cycle arrest but not apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

284.31

Formula

C₁₇H₁₆O₄

CAS No.

104594-70-9

Appearance

Solid

Color

White to off-white

SMILES

O=C(OCCC1=CC=CC=C1)/C=C/C2=CC=C(O)C(O)=C2

Structure Classification

Initial Source

Animals

Propolis

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (351.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.5173 mL	17.5864 mL	35.1729 mL
5 mM	0.7035 mL	3.5173 mL	7.0346 mL
10 mM	0.3517 mL	1.7586 mL	3.5173 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 20 mg/mL (70.35 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.96%

Select Batch:

Data Sheet (277 KB) SDS (252 KB)

COA (244 KB) LCMS (265 KB)

Handling Instructions (2659 KB)

References

[1]. Lin HP, et al. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Oncotarget. 2015 Mar 30;6(9):6684-707. [Content Brief]

Kinase Assay ^[1]	LNCaP 104-R1 cells are treated with 0, 10, 20, or 40 μM Caffeic acid phenethyl ester (CAPE) for 96 h. Three biological replicates of cells are lysed in SDS lysis buffer (240 mM Tris-acetate, 1% SDS, 1% glycerol, 5 mM EDTA pH 8.0) with DTT, protease inhibitors, and a cocktail of phosphatase inhibitors. Micro-Western Arrays are performed to measure protein expression and phosphorylation status modification^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay ^[1]	LNCaP 104-R1 cells are seeded at a density of 3×10³ cells per well in a 96-well plate. After 24 h, the cells are treated with increasing concentrations of Caffeic acid phenethyl ester (CAPE) for 96 h. Cell viability is assessed by an MTT (3,4,5-dimethylthiazol-2-yl)-2–5-diphenyltetrazolium bromide) assay. The amount of formazan is determined by measuring the absorbance at 560 nm using a plate reader. All results are normalized to the average of the control condition in each individual experiment. All experiments are repeated three times. Each time ten wells are utilized for each condition. The mean and standard deviation represent the results from all 30 wells in the three experiments^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Male Balb/c nu/nu mice at age 6 to 8 weeks of age are injected subcutaneously in both flanks with 5×10⁵ LNCaP 104-R1 cells suspended in 0.5 mL of Matrigel and are injected subcutaneously into athymic mice to form tumors. After 14 weeks, the average tumor volume exceeds 150 mm³. The mice are then separated into control group and Caffeic acid phenethyl ester (CAPE) treatment group. Control group contains 6 mice and 8 tumors, while Caffeic acid phenethyl ester treatment group contains 6 mice and 9 tumors. Caffeic acid phenethyl ester (10 mg/kg/day in sesame oil) or vehicle (sesame oil) is administered by gavage starting from 14th week after cancer cell injection. Tumor volume and body weight of mice carrying 104-R1 xenografts are measured weekly using calipers and volume is calculated using the formula volume=length×width×height×0.52^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Lin HP, et al. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Oncotarget. 2015 Mar 30;6(9):6684-707. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.5173 mL	17.5864 mL	35.1729 mL	87.9322 mL
	5 mM	0.7035 mL	3.5173 mL	7.0346 mL	17.5864 mL
	10 mM	0.3517 mL	1.7586 mL	3.5173 mL	8.7932 mL
	15 mM	0.2345 mL	1.1724 mL	2.3449 mL	5.8621 mL
	20 mM	0.1759 mL	0.8793 mL	1.7586 mL	4.3966 mL
	25 mM	0.1407 mL	0.7035 mL	1.4069 mL	3.5173 mL
	30 mM	0.1172 mL	0.5862 mL	1.1724 mL	2.9311 mL
	40 mM	0.0879 mL	0.4397 mL	0.8793 mL	2.1983 mL
	50 mM	0.0703 mL	0.3517 mL	0.7035 mL	1.7586 mL
	60 mM	0.0586 mL	0.2931 mL	0.5862 mL	1.4655 mL
	80 mM	0.0440 mL	0.2198 mL	0.4397 mL	1.0992 mL
	100 mM	0.0352 mL	0.1759 mL	0.3517 mL	0.8793 mL